Veradermics Incorporated Common Stock (MANE)

FairStock Score: 18/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Veradermics is a clinical-stage biotechnology company with 37 employees, not an operating business with sales. The filed figures show no revenue. In FY2025, the year ended 2025-12-31, net loss was $70.0M, worse than the $26.5M loss in FY2024. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $27.2M; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $23.5M. Those compare with losses of $12.4M in fiscal Q1 2025 and $15.6M in fiscal Q2 2025. Free cash flow was -$78.3M TTM, a -1.6% FCF yield on the $4.9B market cap at the 2026-10-13 close. The company has no debt, with D/E 0.00, but cash burn is real. FairStock calculates P/E -46.69, P/B of 5.97, ROE -72.06%, ROCE -43.45%, Piotroski 1/9, Altman Z 241.31, and a FairStock score 18/100. The high Altman figure looks like a balance-sheet artifact, not proof of earning power. The pipeline—VDPHL01 for pattern hair loss and VDMN for common warts—could have intellectual property or regulatory exclusivity if approved, but I see no proven moat, pricing power, or commercial channel today. The Lynch category is none because only two years of filed results exist, and three are needed. Valuation is hope-based: a $4.9B market value for a business with negative earnings and no revenue. Graham would demand evidence and a margin of safety; Buffett would stay inside a circle of competence. I would watch trial data, approvals, cash runway, and share count—not the chart.

In plain English: Veradermics is a small clinical-stage drug company trying to develop treatments for hair loss and skin conditions. The business looks weak today: it has no sales, loses money, and burns cash, according to the filed figures. At $116.26 on 2026-10-13 and a $4.9B market value, the price looks expensive compared with the current numbers, though the value depends on whether its drugs ever succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer